CA2772033C - Compositions and methods for bone formation and remodeling - Google Patents

Compositions and methods for bone formation and remodeling Download PDF

Info

Publication number
CA2772033C
CA2772033C CA2772033A CA2772033A CA2772033C CA 2772033 C CA2772033 C CA 2772033C CA 2772033 A CA2772033 A CA 2772033A CA 2772033 A CA2772033 A CA 2772033A CA 2772033 C CA2772033 C CA 2772033C
Authority
CA
Canada
Prior art keywords
lrp5
wnt
cells
compounds
dkkl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2772033A
Other languages
English (en)
French (fr)
Other versions
CA2772033A1 (en
Inventor
Yazhou Zhang
Peng Liu
Xiaofeng Li
Jie Zhang
Jufang Shan
Dean Engelhardt
Dianqing Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzo Therapeutics Inc
Original Assignee
Enzo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Therapeutics Inc filed Critical Enzo Therapeutics Inc
Publication of CA2772033A1 publication Critical patent/CA2772033A1/en
Application granted granted Critical
Publication of CA2772033C publication Critical patent/CA2772033C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2772033A 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling Expired - Lifetime CA2772033C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/849,067 2004-05-19
US10/849,067 US8637506B2 (en) 2003-09-22 2004-05-19 Compositions and methods for bone formation and remodeling
CA2567023A CA2567023C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2567023A Division CA2567023C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling

Publications (2)

Publication Number Publication Date
CA2772033A1 CA2772033A1 (en) 2005-12-08
CA2772033C true CA2772033C (en) 2016-05-17

Family

ID=35451375

Family Applications (6)

Application Number Title Priority Date Filing Date
CA2771941A Expired - Lifetime CA2771941C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2567023A Expired - Lifetime CA2567023C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2771951A Expired - Lifetime CA2771951C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2772029A Expired - Lifetime CA2772029C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2772033A Expired - Lifetime CA2772033C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2771940A Expired - Lifetime CA2771940C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CA2771941A Expired - Lifetime CA2771941C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2567023A Expired - Lifetime CA2567023C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2771951A Expired - Lifetime CA2771951C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling
CA2772029A Expired - Lifetime CA2772029C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2771940A Expired - Lifetime CA2771940C (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling

Country Status (7)

Country Link
US (1) US8637506B2 (enExample)
EP (3) EP3150255A1 (enExample)
JP (1) JP2008505190A (enExample)
CN (1) CN101316627A (enExample)
CA (6) CA2771941C (enExample)
IL (1) IL179241A (enExample)
WO (1) WO2005115354A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) * 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
EP1401269A4 (en) * 2001-05-11 2005-09-28 Wyeth Corp TRANSGENIC ANIMAL MODEL FOR MODULATING THE BONE MASS
US20040221326A1 (en) * 2001-05-11 2004-11-04 Philip Babij Transgenic animal model of bone mass modulation
US20030219793A1 (en) * 2002-10-04 2003-11-27 Carulli John P. High bone mass gene of 11q13.3
US7485460B2 (en) * 2003-05-21 2009-02-03 Tulane University Health Sciences Center Enhanced growth of adult stem cells with Dkk-1
US8367822B2 (en) * 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US20100041599A1 (en) 2006-11-14 2010-02-18 Dakai Liu Compositions and methods for bone formation, bone remodeling and toxin protection
US20120178697A9 (en) * 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US9052324B2 (en) * 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
WO2008134752A2 (en) * 2007-04-30 2008-11-06 Washington University Methods and compositions for the treatment of cancer
WO2008144659A2 (en) * 2007-05-18 2008-11-27 Board Of Regents, The University Of Texas System Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
EP2567709B1 (en) * 2007-11-02 2017-12-27 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
EP2220247A4 (en) 2007-11-16 2011-10-26 Nuvelo Inc ANTIBODY AGAINST LRP6
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
US8703708B2 (en) 2009-03-18 2014-04-22 The Brigham And Women's Hospital, Inc. Agents and methods for tissue repair and regeneration
WO2010131185A1 (en) 2009-05-12 2010-11-18 Pfizer Inc. Blocking anti-dkk-1 antibodies and their uses
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
CN103237811A (zh) 2010-05-06 2013-08-07 诺瓦提斯公司 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
US9403882B2 (en) 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
KR20140038358A (ko) * 2011-01-11 2014-03-28 페이트 세러퓨틱스, 인코포레이티드 신규의 Wnt 조성물 및 이러한 조성물의 치료학적 용도
KR101303941B1 (ko) 2011-03-31 2013-09-05 연세대학교 산학협력단 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
CN103966229A (zh) * 2014-05-09 2014-08-06 中山大学 bbeAMP基因、其编码的蛋白质、以bbeAMP为目的基因生产的融合蛋白及其应用
WO2016040895A1 (en) 2014-09-12 2016-03-17 xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Wnt signaling agonist molecules
CN106367517A (zh) * 2016-09-28 2017-02-01 湖北工业大学 一种低密度脂蛋白受体相关蛋白5基因突变检测的试剂及应用
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
EP3731867A4 (en) 2017-12-19 2022-04-06 Surrozen Operating, Inc. Anti-lrp5/6 antibodies and methods of use
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN111632147A (zh) * 2020-06-07 2020-09-08 重庆医科大学 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
CN115309402B (zh) * 2022-07-13 2023-10-24 国网江苏省电力有限公司信息通信分公司 一种可量化差异的异构执行程序集合构成方法及装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562623A (en) * 1979-06-21 1981-01-12 Matsushita Electric Industrial Co Ltd Electrode
DE69420649T2 (de) * 1993-08-19 2000-05-04 Advanced Micro Devices, Inc. Voll differentieller Operationsverstärker mit niedriger Versorgungsspannung
US7244577B2 (en) 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3510200A (en) * 1999-03-05 2000-09-21 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
CA2404658A1 (en) 2000-03-29 2001-10-04 Ismail Moarefi 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005511593A (ja) 2001-11-08 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 骨粗鬆症を治療するための組成物及び方法
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US20120178697A9 (en) 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8343922B2 (en) 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
EP1786837B1 (en) 2004-08-04 2013-05-01 Amgen Inc., Antibodies to dkk-1
WO2006089114A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating an anthrax toxin mediated condition

Also Published As

Publication number Publication date
CA2772033A1 (en) 2005-12-08
CA2567023C (en) 2012-07-03
US8637506B2 (en) 2014-01-28
CA2772029A1 (en) 2005-12-08
CA2567023A1 (en) 2005-12-08
CN101316627A (zh) 2008-12-03
JP2008505190A (ja) 2008-02-21
CA2771951C (en) 2014-07-08
US20050196349A1 (en) 2005-09-08
CA2771951A1 (en) 2005-12-08
EP2409732B1 (en) 2016-04-06
EP1758562A2 (en) 2007-03-07
CA2771941C (en) 2015-03-31
IL179241A (en) 2016-04-21
CA2771940C (en) 2016-01-12
EP2409732A1 (en) 2012-01-25
IL179241A0 (en) 2007-03-08
US20060198791A2 (en) 2006-09-07
EP1758562B1 (en) 2012-12-05
CA2771940A1 (en) 2005-12-08
EP3150255A1 (en) 2017-04-05
CA2772029C (en) 2016-05-17
WO2005115354A3 (en) 2007-09-13
CA2771941A1 (en) 2005-12-08
EP1758562A4 (en) 2009-07-22
WO2005115354A2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
CA2772033C (en) Compositions and methods for bone formation and remodeling
JP4993623B2 (ja) スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害
Zhang et al. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd
Mason et al. Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop
Li et al. Activation of FAK and Src are receptor-proximal events required for netrin signaling
Wei et al. R-spondin1 is a high affinity ligand for LRP6 and induces LRP6 phosphorylation and β-catenin signaling
Semënov et al. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6
Gong et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
Li et al. PLC-γ1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration
Kwon et al. Myocilin is a modulator of Wnt signaling
RU2604805C2 (ru) Внеклеточный домен тирозинкиназного рецептора, связывающий аллостерический ингибитор
US8716243B2 (en) Methods of effecting Wnt signaling through Dkk structural analysis
HK1150962A (en) Sclerostin and the inhibition of wnt signaling and bone formation
Ai The Consequences of LRP5 Mutations on the Skeleton

Legal Events

Date Code Title Description
EEER Examination request